Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate

Arthritis and Rheumatism

Volumn 65, Issue 11, 2013, Pages 2803-2813

  De Rotte, M C F J ^a   De Jong, P H P ^a   Pluijm, S M F ^a   C̈alasan, M Bulatovic̈ ^b   Barendregt, P J ^c   Van Zeben, D ^d   Van Der Lubbe, P A ^e   De Sonnaville, P B ^f   Lindemans, J ^a   Hazes, J M W ^a   De Jonge, R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Maasstad Hospital   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

^e Vlietland Hospital   (Netherlands)

^f Admiraal de Ruyter Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CORTICOSTEROID; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; HYDROXYCHLOROQUINE; METHOTREXATE; PYRIDOXINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BONE MARROW DEPRESSION; COHORT ANALYSIS; CORRELATION ANALYSIS; DAS28; DISEASE ACTIVITY; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG TREATMENT FAILURE; ERYTHROCYTE LEVEL; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MENTAL DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUG MONITORING; ERYTHROCYTES; FEMALE; FOLIC ACID; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; VITAMIN B 12; VITAMIN B 6;

EID: 84886785325     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38113     Document Type: Article

References (32)

1. Stamp LK, Roberts RL,. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics 2011; 12: 1449-63.
2. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
3. Raza K,. Early rheumatoid arthritis-the window narrows. Rheumatology (Oxford) 2010; 49: 406-10.
4. Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al, for the Pharmacogenetics Collaborative Research Group. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007; 56: 1765-75.
5. Bulatovic M, Heijstek MW, Van Dijkhuizen EH, Wulffraat NM, Pluijm SM, de Jonge R,. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis 2012; 71: 1484-9.
6. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C,. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 2010; 62: 1128-43.
7. Chan ES, Cronstein BN,. Methotrexate-how does it really work? Nat Rev Rheumatol 2010; 6: 175-8.
8. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64: 1180-5.
9. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton C, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010; 62: 359-68.
10. Claessen SJ, Hazes JM, Huisman MA, van Zeben D, Luime JJ, Weel AE,. Use of risk stratification to target therapies in patients with recent onset arthritis: design of a prospective randomized multicenter controlled trial. BMC Musculoskelet Disord 2009; 10: 71.
11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
12. Ducros V, Belva-Besnet H, Casetta B, Favier A,. A robust liquid chromatography tandem mass spectrometry method for total plasma homocysteine determination in clinical practice. Clin Chem Lab Med 2006; 44: 987-90.
13. Van Zelst BD, de Jonge R,. A stable isotope dilution LC-ESI-MS/MS method for the quantification of pyridoxal-5′-phosphate in whole blood. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 903: 134-41.
14. Zemlin AE, Essack Y, Rensburg M, Keller T, Brinkmann T,. Stability of red blood cell folate in whole blood and haemolysate. Clin Lab 2010; 56: 391-6.
15. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
16. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
17. Fisher MC, Cronstein BN,. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009; 36: 539-45.
18. De Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013; 72: 72-8.
19. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P,. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000:CD000951.
20. Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005; 52: 3030-8.
21. Den Boer E, Meesters RJ, van Zelst BD, Luider TM, Hazes JM, Heil SG, et al. Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS-based method. Anal Bioanal Chem 2013; 405: 1673-81.
22. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 2009; 60: 2248-56.
23. De Rotte MC, Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RH, et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol 2012; 39: 2032-40.
24. Van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 658-65.
25. Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 79-84.
26. Morgan SL, Baggott JE, Lee JY, Alarcon GS,. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25: 441-6.
27. Morgan SL, Baggott JE, Refsum H, Ueland PM,. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clin Pharmacol Ther 1991; 50: 547-56.
28. Sakakeeny L, Roubenoff R, Obin M, Fontes JD, Benjamin EJ, Bujanover Y, et al. Plasma pyridoxal-5-phosphate is inversely associated with systemic markers of inflammation in a population of U.S. adults. J Nutr 2012; 142: 1280-5.
29. 6: a challenging link between nutrition and inflammation in CVD. Br J Nutr 2011; 106: 183-95.
30. Salliot C, van der Heijde D,. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68: 1100-4.
31. Becker ML, van Haandel L, Gaedigk R, Thomas B, Hoeltzel MF, Lasky A, et al. Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability. Pharmacogenet Genomics 2012; 22: 236-46.
32. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 9-18.